USA – Johnson & Johnson’s Biosense Webster has launched the Octaray mapping catheter with TRUEref technology designed for mapping cardiac arrhythmias, including Atrial fibrillation (AFib).
It is powered by the company’s Carto 3 Version 7 system. In a press release, Biosense Webster details that Octaray has eight splines with improved electrode spacing options.
This offers shorter and more efficient mapping times compared to its Pentaray catheter. Increased efficiency and speed could shorten overall ablation procedure times, the company said.
The Octaray mapping catheter can map arrhythmias in any chamber and provides physicians with precise information for their catheter ablation procedures.
The catheter has 48 small mapping electrodes on eight splines, reduced electrode size, and tight electrode spacing.
AFib is the most common type of cardiac arrhythmia and impacts nearly 40 million people worldwide.
AFib is a progressive disease, and if left untreated can get worse over time or lead to other serious complications like heart disease or stroke.
Catheter ablation is a safe and effective procedure to restore the heart’s incorrect electrical signals, which cause an abnormal heart rhythm.
The Octaray mapping catheter can map arrhythmias in any chamber and provides physicians with precise information for their catheter ablation procedures.
With shorter and more efficient mapping time, the catheter benefits both the patient and the physician, allowing for shorter procedure times while enabling greater accuracy and detail.
TRUEref technology, a novel mapping reference electrode, reduces the impact of farfield signals. It helps to accurately identify lesion set gaps and improve the characterization of lesion sets.
“With more splines and electrodes, the increased surface area coverage and improved signal quality with the Octaray mapping catheter allows me to better understand the anatomy and conduction properties of the chamber of interest,” said Dr. Amit Thosani, director of cardiac electrophysiology at Allegheny Health Network.
“This catheter not only helps me to map more accurately and efficiently, but also allows for better patient-specific therapy.”
Octaray with TRUEref technology is now available in the US and EMEA and has been both CE marked and 510(k) cleared by the US Food and Drug Administration (FDA).
Liked this article? Sign up to receive our regular email newsletters, focused on Africa and World’s healthcare industry, directly into your inbox. SUBSCRIBE HERE
